Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.
Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.
复制标题
每日高剂量口服维生素 D 治疗对 COVID 19 疾病患者炎症标志物的影响。
DOI：
10.1038/s41598-021-90189-4
复制
发表时间：
2021-05-20
影响因子：
4.6
通讯作者：
Kandakatla M
中科院分区：
文献类型：
--
作者：
Lakkireddy M;Gadiga SG;Malathi RD;Karra ML;Raju ISSVPM;Ragini;Chinapaka S;Baba KSSS;Kandakatla M
已知COVID 19会导致免疫失调，维生素D是一种已知的免疫调节剂。本研究旨在客观地研究Pulse D疗法在减少COVID-19炎症标志物方面的影响。在第0天和第9/11天，根据各自的BMI类别，对患有维生素D缺乏症的COVID-19确诊患者的炎症标志物（N/L比率、CRP、LDH、IL 6、铁蛋白）以及维生素D进行了沿着评价。受试者被随机分配至VD组和NVD组。VD组在标准治疗的基础上接受Pulse D治疗（根据BMI，每天补充60，000 IU维生素D，持续8或10天）。NVD组仅接受标准治疗。分析两组之间变量的差异是否具有统计学意义。87/130例受试者完成了研究（VD：44，NVD：43）。VD组维生素D水平在脉冲D治疗后从16 ± 6 ng/ml增加到89 ± 32 ng/ml，并且注意到所有测量的炎症标志物高度显著（p < 0.01）降低。NVD组各项指标下降不明显（p > 0.05）。两组间标记物减少的差异（NVD vs VD）非常显著（p < 0.01）。将维生素D的治疗性改善至80-100 ng/ml，显著降低了与COVID-19相关的炎症标志物，且无任何副作用。因此，连续脉冲D疗法可以安全地添加到现有的COVID-19治疗方案中，以改善疗效。
COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the impact of Pulse D therapy in reducing the inflammatory markers of COVID-19. Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0th day and 9th/11th day as per their respective BMI category. Subjects were randomised into VD and NVD groups. VD group received Pulse D therapy (targeted daily supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 16 ± 6 ng/ml to 89 ± 32 ng/ml after Pulse D therapy in VD group and highly significant (p < 0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p > 0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p < 0.01). Therapeutic improvement in vitamin D to 80–100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive Pulse D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.
登录
查看更多内容
影响因子：
4.7
作者：
Ebadi, Maryam;Montano-Loza, Aldo J.
通讯作者：
Montano-Loza, Aldo J.
影响因子：
3.7
作者：
Maghbooli Z;Sahraian MA;Ebrahimi M;Pazoki M;Kafan S;Tabriz HM;Hadadi A;Montazeri M;Nasiri M;Shirvani A;Holick MF
通讯作者：
Holick MF
影响因子：
13.8
作者：
Meltzer, David O.;Best, Thomas J.;Solway, Julian
通讯作者：
Solway, Julian
DOI：
10.3760/cma.j.issn.1001-0939.2020.0005
发表时间：
2020-02-06
期刊：
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
影响因子：
--
作者：
Chen, L;Liu, H G;Wei, S
通讯作者：
Wei, S
影响因子：
3.5
作者：
De Smet, Dieter;De Smet, Kristof;Martens, Geert A.
通讯作者：
Martens, Geert A.